文献速递神经PETMR

MGMT启动子甲基化状态对胶质瘤[18F]FET摄取和脑血流量无影响:基于立体定向影像的组织学验证研究

MGMT promoter methylation status shows no effect on [18F]FET uptake and CBF in gliomas: a stereotactic image-based histological validation study.
PubMed 文献 · Eur Radiol · 2022-02-22

本研究纳入57例新诊断胶质瘤患者,用混合PET/MR评估MGMT启动子甲基化状态对[18F]FET摄取和ASL脑血流量的影响,并以立体定向活检验证。全肿瘤分析和活检位点分析均显示TBRmean、TBRmax、nCBFmean、nCBFmax在甲基化组与非甲基化组间无统计学显著差异(均p>0.05),且与甲基化百分比无相关性。

要点

  • 全肿瘤VOI分析显示MGMT启动子甲基化状态对[18F]FET摄取和ASL脑血流量无影响。
  • 在WHO IV级胶质母细胞瘤中,[18F]FET PET和ASL参数未能预测MGMT启动子甲基化状态。
  • 基于立体定向影像的组织学显示[18F]FET摄取和脑血流量与MGMT启动子甲基化状态及百分比无相关性。

核心结论

  • MGMT启动子甲基化状态对胶质瘤的[18F]FET摄取和ASL脑血流量无影响,立体定向活检验证了这一点,并进一步揭示[18F]FET PET摄取和脑血流量与MGMT启动子甲基化百分比无相关性。

研究设计与样本

  • 研究纳入57例新诊断胶质瘤患者,基于PET/FLAIR影像勾画全肿瘤和参考VOI并转移至相应的[18F]FET PET和CBF图,计算平均和最大肿瘤-脑比值(TBR)及标准化CBF(nCBF),采用全肿瘤分析和立体定向活检评估预测效能,并用多个立体定向活检获取的组织学标本分析PET/MR参数与MGMT启动子甲基化的相关性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To investigate the effects of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation status of gliomas on O-(2-18F-fluoroethyl)-L-tyrosine ([18F]FET) uptake and cerebral blood flow (CBF) of arterial spin labeling (ASL), evaluated by hybrid PET/MR. Stereotactic biopsy was used to validate the findings.

METHODS: A set of whole tumor and reference volumes of interest (VOIs) based on PET/FLAIR imaging were delineated and transferred to the corresponding [18F]FET PET and CBF maps in 57 patients with newly diagnosed gliomas. The mean and max tumor-to-brain ratio (TBR) and normalized CBF (nCBF) were calculated. The predictive efficacy of [18F]FET PET and CBF in determining MGMT promoter methylation status of glioma were evaluated by whole tumor analysis and stereotactic biopsy. The correlation between PET/MR parameters and MGMT promoter methylation were analyzed using histological specimens acquired from multiple stereotactic biopsies.

RESULTS: Based on the analysis of whole tumor volume and biopsy site, TBRmean, TBRmax, nCBFmean, and nCBFmax showed no statistically significant differences between gliomas with and without MGMT promoter methylation (all p > 0.05). Furthermore, stereotactic biopsy demonstrated that TBRmean, TBRmax, nCBFmean, and nCBFmax showed no correlation with MGMT promoter methylation (r = -0.117, p = 0.579; r = -0.161, p = 0.443; r = -0.271, p = 0.191; r = -0.300, p = 0.145; respectively).

CONCLUSIONS: MGMT promoter methylation status shows no effect on [18F]FET uptake and CBF of ASL in gliomas. Stereotactic biopsy validates it and further reveals there is no correlation of [18F]FET PET uptake and CBF with the percentages of MGMT promoter methylation.

KEY POINTS: • Based on whole tumor VOI assessment, MGMT promoter methylation status shows no effect on [18F]FET uptake and CBF of ASL in gliomas. • For WHO grade IV glioblastomas, [18F]FET PET and ASL parameters based on hybrid PET/MR fail to predict the MGMT promoter methylation status. • Stereotactic image-based histology reveals that there is no correlation of [18F]FET PET uptake and CBF with the status and percentages of MGMT promoter methylation in gliomas.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Song, Shan, Wang, et al. MGMT promoter methylation status shows no effect on [18F]FET uptake and CBF in gliomas: a stereotactic image-based histological validation study. Eur Radiol. 2022. PMID: 35192012. doi:10.1007/s00330-022-08606-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。